HC Wainwright Has Pessimistic Opinion of NAGE Q1 Earnings

Niagen Bioscience, Inc. (NASDAQ:NAGE) – Equities researchers at HC Wainwright lowered their Q1 2027 earnings per share (EPS) estimates for shares of Niagen Bioscience in a research report issued on Wednesday, November 4th. HC Wainwright analyst R. Selvaraju now anticipates that the company will earn ($0.01) per share for the quarter, down from their prior forecast of $0.03. The consensus estimate for Niagen Bioscience’s current full-year earnings is $0.08 per share. HC Wainwright also issued estimates for Niagen Bioscience’s Q2 2027 earnings at $0.01 EPS, Q3 2027 earnings at $0.02 EPS and Q4 2027 earnings at $0.03 EPS.

Niagen Bioscience (NASDAQ:NAGE) last issued its quarterly earnings data on Wednesday, November 4th. The company reported ($0.01) earnings per share for the quarter, meeting analysts’ consensus estimates of ($0.01). Niagen Bioscience had a return on equity of 17.95% and a net margin of 12.39%. The company had revenue of $27.19 million for the quarter.

Several other analysts have also commented on NAGE. Roth Capital reissued a “buy” rating on shares of Niagen Bioscience in a research report on Wednesday, August 5th. Canaccord Genuity Group lowered their price target on shares of Niagen Bioscience from $10.00 to $9.00 and set a “buy” rating on the stock in a report on Friday, October 30th. Finally, Weiss Ratings reaffirmed a “hold (c)” rating on shares of Niagen Bioscience in a research report on Thursday, October 15th. One investment analyst has rated the stock with a Strong Buy rating, three have issued a Buy rating and one has issued a Hold rating to the stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Buy” and an average price target of $10.00.

Niagen Bioscience Price Performance

NAGE opened at $2.52 on Thursday. The firm has a market capitalization of $200.70 million, a PE ratio of 14.00 and a beta of 2.12. The business’s 50-day moving average is $2.81 and its two-hundred day moving average is $3.87. Niagen Bioscience has a 1 year low of $2.31 and a 1 year high of $7.95.

Institutional Investors Weigh In On Niagen Bioscience

A number of large investors have recently modified their holdings of NAGE. SteelPeak Wealth LLC acquired a new position in shares of Niagen Bioscience during the first quarter valued at about $14,875,000. Tieton Capital Management LLC purchased a new stake in Niagen Bioscience during the 2nd quarter worth approximately $6,407,000. Arrowstreet Capital Limited Partnership grew its position in Niagen Bioscience by 47.1% during the 1st quarter. Arrowstreet Capital Limited Partnership now owns 2,378,437 shares of the company’s stock worth $10,489,000 after purchasing an additional 761,685 shares during the last quarter. Sei Investments Co. grew its position in Niagen Bioscience by 155.6% during the 1st quarter. Sei Investments Co. now owns 971,574 shares of the company’s stock worth $4,285,000 after purchasing an additional 591,495 shares during the last quarter. Finally, Renaissance Technologies LLC increased its stake in Niagen Bioscience by 45.4% during the 1st quarter. Renaissance Technologies LLC now owns 1,328,843 shares of the company’s stock valued at $5,860,000 after purchasing an additional 414,725 shares in the last quarter. Hedge funds and other institutional investors own 15.41% of the company’s stock.

About Niagen Bioscience

Niagen Bioscience, Inc develops and commercializes science-based products designed to support healthy aging and cellular health. The company focuses on NAD+ biology, including nicotinamide riboside (NR), a form of vitamin B3 that serves as a precursor to NAD+, a coenzyme involved in cellular energy production and other biological processes.

Its principal consumer product is Tru Niagen, an NR-based dietary supplement sold through the company’s direct-to-consumer website and retail and distribution channels.